Geron Corp (GERN) shareholders
Close on Nov 17, 2026Market cap $642.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 66,502,728 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 63,988,106 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 42,172,679 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
| Soleus Capital, LLC Joint filing with Soleus Capital Master Fund, L.P. (6.50%), Soleus Capital Group, LLC (6.50%) and 3 more | 41,508,659 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.50%), David Kroin (5.50%) | 35,000,000 | 5.50% | 13G (passive) | Mar 18, 2025 |
| Soleus Capital Group, LLC Joint filing with Soleus Capital Master Fund, L.P. (5.20%), Soleus Capital, LLC (5.20%) and 3 more | 33,008,659 | 5.20% | 13G (passive) | Feb 25, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (5.09%), Deep Track Biotechnology Master Fund, Ltd. (5.09%) | 32,511,271 | 5.09% | 13G (passive) amendment | Dec 31, 2025 |
| State Street Corporation | 31,896,515 | 5.00% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GERN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 49,115,571 | 7.64% | $62.87M | +1,795,792 | 0.00% |
| Ra Capital Management, L.P. | 42,809,751 | 6.66% | $54.80M | −20,961,615 | 0.48% |
| Soleus Capital Management, L.P. | 42,808,659 | 6.66% | $54.80M | +1,300,000 | 1.89% |
| State Street Corp | 35,856,671 | 5.58% | $45.90M | +5,359,488 | 0.00% |
| Citadel Advisors LLC | 29,038,928 | 4.52% | $37.17M | +7,462,359 | 0.00% |
| Vanguard Capital Management LLC | 27,250,215 | 4.24% | $34.88M | +581,186 | 0.00% |
| Nantahala Capital Management, LLC | 24,450,000 | 3.81% | $31.30M | +13,225,000 | 0.52% |
| Clearbridge Investments, LLC | 19,648,853 | 3.06% | $25.15M | +28,533 | 0.02% |
| Eversept Partners, LP | 18,717,422 | 2.91% | $23.96M | −117,461 | 1.24% |
| Goldman Sachs Group Inc | 16,633,368 | 2.59% | $21.29M | +5,456,777 | 0.00% |
| Geode Capital Management, LLC | 14,555,954 | 2.27% | $18.64M | +885,169 | 0.00% |
| Morgan Stanley | 12,945,431 | 2.01% | $16.57M | +280,312 | 0.00% |
| Vanguard Portfolio Management LLC | 10,812,598 | 1.68% | $13.84M | +6,143,815 | 0.00% |
| Vivo Capital, LLC | 8,671,797 | 1.35% | $11.10M | – | 1.01% |
| Millennium Management LLC | 8,112,267 | 1.26% | $10.38M | +790,745 | 0.00% |
| Kynam Capital Management, LP | 6,836,318 | 1.06% | $8.75M | – | 0.48% |
| Candriam S.C.A. | 5,589,182 | 0.87% | $7.15M | +1,667,706 | 0.03% |
| FMR LLC | 5,502,807 | 0.86% | $7.04M | −1,094,349 | 0.00% |
| Pale Fire Capital SE | 5,307,204 | 0.83% | $6.79M | +418,900 | 0.48% |
| Northern Trust Corp | 5,032,212 | 0.78% | $6.44M | +169,948 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 260 | 489M | 76.1% | 37 / 96 | 62 / 30 | 79M | 85M |
| Q1 2026 | 256 | 497M | 77.4% | 37 / 90 | 56 / 38 | 124M | 69M |
| Q4 2025 | 262 | 479M | 74.5% | 30 / 65 | 99 / 29 | 32M | 62M |
| Q3 2025 | 263 | 509M | 79.2% | 35 / 72 | 89 / 29 | 60M | 66M |
| Q2 2025 | 259 | 515M | 80.1% | 32 / 96 | 72 / 40 | 79M | 74M |
| Q1 2025 | 270 | 510M | 79.4% | 46 / 100 | 66 / 59 | 163M | 140M |
| Q4 2024 | 285 | 489M | 76.2% | 66 / 90 | 65 / 32 | 87M | 107M |
| Q3 2024 | 255 | 510M | 79.4% | 45 / 87 | 59 / 27 | 182M | 91M |
| Q2 2024 | 239 | 465M | 72.4% | 55 / 85 | 51 / 43 | 147M | 123M |
| Q1 2024 | 231 | 443M | 68.9% | 54 / 66 | 64 / 22 | 101M | 64M |
| Q4 2023 | 202 | 406M | 63.1% | 23 / 73 | 47 / 21 | 62M | 28M |
| Q3 2023 | 202 | 371M | 57.8% | 27 / 84 | 34 / 24 | 45M | 18M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
128 funds held GERN in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GERN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 21,816,987 | 3.40% | $27.93M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 20,449,234 | 3.18% | $26.18M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 14,478,730 | 2.25% | $18.53M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 12,981,241 | 2.02% | $16.75M | 0.08% | Jul 31, 2026 |
| ClearBridge Small Cap Growth Fund | 6,316,110 | 0.98% | $8.15M | 0.43% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 6,108,370 | 0.95% | $7.82M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 6,100,057 | 0.95% | $7.87M | 0.02% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 5,452,212 | 0.85% | $6.82M | 0.13% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 5,140,717 | 0.80% | $6.58M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 4,426,859 | 0.69% | $5.67M | 0.06% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 2,804,965 | 0.44% | $3.51M | 0.02% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 2,794,804 | 0.44% | $3.49M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 2,555,103 | 0.40% | $3.19M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 1,432,603 | 0.22% | $1.79M | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 1,360,078 | 0.21% | $1.75M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Harout Semerjian | President & CEO, Director | 53,500 | 0.01% | Nov 16, 2026 |
| John A. Scarlett | Chairman, President and CEO, Director | 137,500 | 0.02% | Mar 3, 2025 |
| Timothy Williams | EVP and Chief Legal Officer | 12,000 | 0.00% | Nov 16, 2026 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 27,500 | 0.00% | Feb 19, 2026 |
| Joseph Eid | EVP, R&D; Chief Medical Office | – | – | Feb 19, 2026 |
| Ahmed ElNawawi | EVP, Chief Commercial Officer | 10,000 | 0.00% | Oct 20, 2025 |
| James Ziegler | EVP, Chief Commercial Officer | 100,000 | 0.02% | Mar 3, 2025 |
| Scott Alan Samuels | EVP, Chief Legal Officer | 26,682 | 0.00% | Mar 3, 2025 |
| Andrew J. Grethlein | EVP, Chief Operating Officer | 676,615 | 0.11% | Feb 20, 2025 |
| Robert J. Spiegel | Director | 212,161 | 0.03% | Oct 1, 2026 |
| Dawn Carter Bir | Director | – | – | May 26, 2026 |
| Elizabeth G. O'Farrell | Director | 33,627 | 0.01% | May 26, 2026 |
| Susan Molineaux | Director | 165,527 | 0.03% | May 26, 2026 |
| John F. McDonald | Director | – | – | May 26, 2026 |
| Constantine Chinoporos | Director | – | – | Mar 26, 2026 |
| Patricia S. Andrews | Director | – | – | Mar 26, 2026 |
| V. Bryan Lawlis | Director | 13,300 | 0.00% | May 22, 2025 |
| Gaurav Aggarwal | Director | 1,970 | 0.00% | May 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Timothy Williams EVP and Chief Legal Officer | Nov 16, 2026 | Buy | +12,000 | $0.94 | $11.28K | 12,000 |
| Harout Semerjian President & CEO, Director | Nov 13, 2026 | Buy | +53,500 | $0.95 | $50.83K | 53,500 |
| Robert J. Spiegel Director | Sep 30, 2026 | Award | +6,351 | $1.23 | $7.81K | 212,161 |
| Robert J. Spiegel Director | Jun 30, 2026 | Award | +6,103 | $1.28 | $7.81K | 205,810 |
| Robert J. Spiegel Director | Mar 31, 2026 | Award | +5,243 | $1.49 | $7.81K | 199,707 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Option exercise | +27,500 | – | – | 27,500 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sale | −9,855 | $1.94 | $19.12K | 17,645 |
| Robert J. Spiegel Director | Dec 31, 2025 | Award | +5,918 | $1.32 | $7.81K | 194,464 |
| Robert J. Spiegel Director | Sep 30, 2025 | Award | +5,702 | $1.37 | $7.81K | 188,546 |
| Robert J. Spiegel Director | Jun 30, 2025 | Award | +5,540 | $1.41 | $7.81K | 182,844 |
| V. Bryan Lawlis Director | May 9, 2025 | Buy | +13,300 | $1.18 | $15.69K | 13,300 |
| Robert J. Spiegel Director | Mar 31, 2025 | Award | +4,913 | $1.59 | $7.81K | 177,304 |
| James Ziegler EVP, Chief Commercial Officer | Feb 27, 2025 | Buy | +100,000 | $1.60 | $160.00K | 100,000 |
| Scott Alan Samuels EVP, Chief Legal Officer | Feb 27, 2025 | Buy | +15,000 | $1.61 | $24.15K | 26,682 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 27, 2025 | Buy | +12,500 | $1.77 | $22.13K | 12,500 |
| Robert J. Spiegel Director | Dec 31, 2024 | Award | +2,206 | $3.54 | $7.81K | 172,391 |
| Robert J. Spiegel Director | Dec 31, 2024 | Award | −2,206 | – | – | 172,391 |
| Robert J. Spiegel Director | Sep 30, 2024 | Award | +1,767 | $4.54 | $8.02K | 170,185 |
| Robert J. Spiegel Director | Sep 30, 2024 | Award | −1,767 | – | – | 170,185 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Jul 8, 2024 | Option exercise | +674,348 | $1.72 | $1.16M | 674,348 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Jul 8, 2024 | Sale | −674,348 | $4.56 | $3.08M | 0 |
| Robert J. Spiegel Director | Jun 28, 2024 | Award | +1,916 | $4.24 | $8.12K | 168,418 |
| Robert J. Spiegel Director | Jun 28, 2024 | Award | −1,916 | – | – | 168,418 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +20,000 | $1.06 | $21.20K | 20,000 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +112,500 | $1.06 | $119.25K | 112,500 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Sale | −287,900 | $4.63 | $1.33M | 0 |
| Faye Feller EVP, Chief Medical Officer | Jun 10, 2024 | Option exercise | +155,400 | $1.30 | $202.02K | 155,400 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 10, 2024 | Sale | −421,875 | $4.65 | $1.96M | 0 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 10, 2024 | Option exercise | +421,875 | $1.06 | $447.19K | 421,875 |
| John A. Scarlett Chairman, President and CEO, Director | Jun 4, 2024 | Option exercise | +600,000 | $2.54 | $1.52M | 600,000 |
| John A. Scarlett Chairman, President and CEO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −600,000 | $4.00 | $2.40M | 600,000 |
| V. Bryan Lawlis Director | May 15, 2024 | Option exercise | +35,000 | $1.94 | $67.90K | 35,000 |
| V. Bryan Lawlis Director | May 15, 2024 | Sale(10b5-1 plan) | −35,000 | $3.75 | $131.25K | 0 |
| Robert J. Spiegel Director | Mar 29, 2024 | Award | +2,462 | $3.30 | $8.12K | 166,502 |
| Robert J. Spiegel Director | Mar 29, 2024 | Award | −2,462 | – | – | 166,502 |
| Robert J. Spiegel Director | Dec 29, 2023 | Award | +3,406 | – | – | 164,040 |
| Gaurav Aggarwal Director | Dec 29, 2023 | Award | +1,970 | – | – | 1,970 |
| Susan Molineaux Director | Dec 29, 2023 | Award | +6,220 | – | – | 130,527 |
| Susan Molineaux Director | Sep 29, 2023 | Award | +6,191 | – | – | 124,307 |
| Robert J. Spiegel Director | Sep 29, 2023 | Award | +3,390 | – | – | 160,634 |
| Elizabeth G. O'Farrell Director | Aug 24, 2023 | Buy | +6,579 | $2.28 | $15.00K | 26,220 |
| Elizabeth G. O'Farrell Director | Aug 24, 2023 | Buy | +6,607 | $2.28 | $15.06K | 7,407 |
| Robert J. Spiegel Director | Jun 30, 2023 | Award | +2,239 | – | – | 157,244 |
| Anil Kapur EVP, Corp Strategy & CCO | Jun 30, 2023 | Award | +7,567 | $2.04 | $15.44K | 60,783 |
| Susan Molineaux Director | Jun 30, 2023 | Award | +4,088 | – | – | 118,116 |
| V. Bryan Lawlis Director | May 11, 2023 | Option exercise | +35,000 | $1.10 | $38.50K | 35,000 |
| V. Bryan Lawlis Director | May 11, 2023 | Sale(10b5-1 plan) | −35,000 | $3.00 | $105.00K | 0 |
| Susan Molineaux Director | May 1, 2023 | Option exercise | +35,000 | $1.10 | $38.50K | 35,000 |
| Susan Molineaux Director | May 1, 2023 | Sale(10b5-1 plan) | −35,000 | $2.48 | $86.80K | 0 |
| Susan Molineaux Director | Mar 31, 2023 | Award | +6,048 | – | – | 114,028 |
| Robert J. Spiegel Director | Mar 31, 2023 | Award | +3,312 | – | – | 155,005 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 10, 2023 | Sale(10b5-1 plan) | −446,668 | $3.00 | $1.34M | 0 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 10, 2023 | Option exercise | +446,668 | $1.50 | $670.00K | 446,668 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 9, 2023 | Option exercise | +446,666 | $1.50 | $670.00K | 446,666 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 9, 2023 | Sale(10b5-1 plan) | −446,666 | $3.03 | $1.35M | 0 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Sale(10b5-1 plan) | −234,719 | $3.03 | $711.20K | 0 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Option exercise | +150,000 | $1.51 | $226.50K | 384,719 |
| Andrew J. Grethlein EVP, Chief Operating Officer | Feb 9, 2023 | Sale(10b5-1 plan) | −150,000 | $3.03 | $454.50K | 234,719 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 8, 2023 | Option exercise | +446,666 | $1.50 | $670.00K | 446,666 |
| John A. Scarlett Chairman, President and CEO, Director | Feb 8, 2023 | Sale(10b5-1 plan) | −446,666 | $3.08 | $1.38M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Geron's stock actually held short. Settlement fails (shares not delivered on time) peaked at 336,522 shares on Sep 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| James Ziegler Officer | Dec 15, 2025 | 20,000 | $27.40K | Dec 15, 2025 | Open Market Purchase |
| Andrew J. Grethlein Officer | Jul 8, 2024 | 674,348 | $2.93M | Jul 8, 2024 | STOCK OPTION EXERCISE |
| Anil Kapur Officer | Jun 10, 2024 | 421,875 | $1.96M | Jun 10, 2024 | STOCK OPTION EXERCISE |
| Faye Feller Officer | Jun 10, 2024 | 287,900 | $1.34M | Jun 10, 2024 | STOCK OPTION EXERCISE |
| John A. Scarlett Officer, Director | Jun 4, 2024 | 600,000 | $2.40M | Jun 4, 2024 | Stock Option Exercise |
| V. Bryan Lawlis Director | May 15, 2024 | 35,000 | $131.27K | May 15, 2024 | Stock Option Exercise |
| V. Bryan Lawlis Director | May 11, 2023 | 35,000 | $105.00K | May 11, 2023 | Stock Option Exercise |
| Susan Molineaux Director | May 1, 2023 | 35,000 | $86.65K | May 1, 2023 | Stock Options |
See a number that looks wrong?